CD8A and neoplasm: However, multiple preclinical studies combined MEKi with other chemotherapeutic/immunotherapeutic agents, such as anti-PD-1 or anti-PD-L1, to modulate the TME, increase CD8 Teff cells, reduce MDSCs, and reduce tumor proliferation and overall tumor burden (36–39).